Korbevaks (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Korbevaks" in Serbian language version.

refsWebsite

Global rank Serbian rank

2livemint.com

390^th place

low place

1euronews.rs

low place

82^nd place

1ctri.nic.in

low place

1web.archive.org

1^st place

1cepi.net

low place

1bcm.edu

low place

1bbc.com

20^th place

51^st place

1indianexpress.com

60^th place

2,890^th place

1scientificamerican.com

896^th place

686^th place

1theprint.in

987^th place

low place

1thehindu.com

52^nd place

1,504^th place

1worldcat.org

5^th place

12^th place

1archive.today

14^th place

22^nd place

1ndtv.com

138^th place

2,740^th place

1npr.org

92^nd place

305^th place

1theguardian.com

12^th place

43^rd place

1hindustantimes.com

71^st place

2,676^th place

1indiatimes.com

17^th place

443^rd place

archive.today

„India’s Corbevax vaccine was developed at Texas Children’s Hospital. …”. archive.ph. 2022-01-01. Архивирано из оригинала 01. 01. 2022. г. Приступљено 2022-01-23.

bbc.com

„Covovax and Corbevax: What we know about India's new Covid vaccines”. BBC News. 28. 12. 2021.

bcm.edu

„Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India”. Baylor College of Medicine. 16. 11. 2020. Приступљено 23. 1. 2022.

cepi.net

„CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate”. cepi.net. CEPI. 29. 12. 2020. Приступљено 5. 3. 2021.

ctri.nic.in

„A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers.”. ctri.nic.in. Clinical Trials Registry India. 13. 1. 2021. CTRI/2020/11/029032. Архивирано из оригинала 12. 11. 2020. г.

euronews.rs

Tanjug (2021-12-28). „Indija u borbi protiv omikron soja: Odobrene još dve kovid vakcine i lek molnupiravir”. Euronews.rs (на језику: српски). Приступљено 2022-01-23.

hindustantimes.com

„Health ministry buys 300 mn doses of Biological-E’s Covid vaccine in advance”. Hindustan Times (на језику: енглески). 2021-06-03. Приступљено 2022-01-23.

indianexpress.com

Raghavan, Prabha (10. 6. 2021). „Explained: How is Biological E's Corbevax different?”. The Indian Express. Приступљено 29. 12. 2021.

indiatimes.com

timesofindia.indiatimes.com

Jun 5, Swati Bharadwaj / TNN / Updated:; 2021; Ist, 15:04. „Bio E's Corbevax may be India’s cheapest vaccine at Rs 250 per dose | India News - Times of India”. The Times of India (на језику: енглески). Приступљено 2022-01-23.

livemint.com

„Biological E initiates human trials of vaccine”. 16. 11. 2020.
Leo, Leroy (2021-04-24). „Biological E completes phase-2 covid vaccine trial, gets SEC nod for phase-3”. mint (на језику: енглески). Приступљено 2022-01-23.

ndtv.com

„India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points”. NDTV.com. Приступљено 2022-01-23.

npr.org

„A Texas team comes up with a COVID vaccine that could be a global game changer”. NPR.org (на језику: енглески). Приступљено 2022-01-23.

scientificamerican.com

Hotez, Peter J.; Bottazzi, Maria Elena (30. 12. 2021). „A COVID Vaccine for All”. Scientific American. Приступљено 2. 1. 2022.

theguardian.com

„Texas scientists’ new Covid-19 vaccine is cheaper, easier to make and patent-free”. the Guardian (на језику: енглески). 2022-01-15. Приступљено 2022-01-23.

thehindu.com

„Coronavirus | Biological E gets nod to start Phase III trials of COVID-19 vaccine”. The Hindu (на језику: енглески). Special Correspondent. 2021-04-24. ISSN 0971-751X. Приступљено 2022-01-23.

theprint.in

„US assures export of raw materials to India for Covid vaccines as Doval speaks to Sullivan”. ThePrint (на језику: енглески). 2021-04-25. Приступљено 2022-01-23.

web.archive.org

„A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers.”. ctri.nic.in. Clinical Trials Registry India. 13. 1. 2021. CTRI/2020/11/029032. Архивирано из оригинала 12. 11. 2020. г.

worldcat.org

„Coronavirus | Biological E gets nod to start Phase III trials of COVID-19 vaccine”. The Hindu (на језику: енглески). Special Correspondent. 2021-04-24. ISSN 0971-751X. Приступљено 2022-01-23.